Schrenk HH - Search Results

1

Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.

Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H. Stehle G, et al. Among authors: schrenk hh. Anticancer Drugs. 1999 Sep;10(8):785-90. Anticancer Drugs. 1999. PMID: 10573211

2

Enhanced albumin uptake by rat tumors.

Wunder A, Stehle G, Sinn H, Schrenk H, Hoffbiederbeck D, Bader F, Friedrich E, Peschke P, Maierborst W, Heene D. Wunder A, et al. Int J Oncol. 1997 Sep;11(3):497-507. doi: 10.3892/ijo.11.3.497. Int J Oncol. 1997. PMID: 21528238

3

Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats.

Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H. Stehle G, et al. Among authors: schrenk hh. Anticancer Drugs. 1999 Apr;10(4):405-11. doi: 10.1097/00001813-199904000-00009. Anticancer Drugs. 1999. PMID: 10378676

4

Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.

Stehle G, Wunder A, Sinn H, Schrenk HH, Schütt S, Frei E, Hartung G, Maier-Borst W, Heene DL. Stehle G, et al. Among authors: schrenk hh. Anticancer Drugs. 1997 Oct;8(9):835-44. doi: 10.1097/00001813-199710000-00004. Anticancer Drugs. 1997. PMID: 9402310

5

Pharmacokinetic properties of LMW-heparin-tyramine fractions with high or low affinity to antithrombin III in the rat.

Stehle G, Wunder A, Sinn H, Schrenk HH, Harenberg J, Malsch R, Maier-Borst W, Heene DL. Stehle G, et al. Among authors: schrenk hh. Semin Thromb Hemost. 1997;23(1):31-7. doi: 10.1055/s-2007-996067. Semin Thromb Hemost. 1997. PMID: 9156408

6

Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats.

Stehle G, Wunder A, Sinn H, Schrenk HH, Friedrich EA, Dempfle CE, Maier-Borst W, Heene DL. Stehle G, et al. Among authors: schrenk hh. J Surg Res. 1995 Feb;58(2):197-204. doi: 10.1006/jsre.1995.1031. J Surg Res. 1995. PMID: 7861773

7

Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone.

Weigand M, Hartung G, Roboz J, Sieger S, Wolf M, Sinn H, Schrenk HH, Wiessler M, Frei E. Weigand M, et al. Among authors: schrenk hh. Anticancer Drug Des. 2001 Aug-Oct;16(4-5):227-37. Anticancer Drug Des. 2001. PMID: 12049481

8

Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma.

Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, Sinn H. Wunder A, et al. Among authors: schrenk hh. Int J Cancer. 1998 Jun 10;76(6):884-90. doi: 10.1002/(sici)1097-0215(19980610)76:6<884::aid-ijc19>3.0.co;2-2. Int J Cancer. 1998. PMID: 9626357

9

Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.

Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kränzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W. Hartung G, et al. Among authors: schrenk hh. Clin Cancer Res. 1999 Apr;5(4):753-9. Clin Cancer Res. 1999. PMID: 10213209 Clinical Trial.

10

The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.

Stehle G, Sinn H, Wunder A, Schrenk HH, Schütt S, Maier-Borst W, Heene DL. Stehle G, et al. Among authors: schrenk hh. Anticancer Drugs. 1997 Aug;8(7):677-85. Anticancer Drugs. 1997. PMID: 9311444

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results